Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: Current practice
Nathan Lawrentschuk,
Ian D Davis,
Damien M Bolton,
Andrew M Scott,
Corresponding Author
Nathan Lawrentschuk
University of Melbourne, Departments of Surgery and
Ludwig Institute for Cancer Research, and
Dr Nathan Lawrentschuk, md, 10 Mary Street, Beaumaris, Vic. 3193, Australia. Email: [email protected]Search for more papers by this authorIan D Davis
Ludwig Institute for Cancer Research, and
Medicine,
Search for more papers by this authorDamien M Bolton
University of Melbourne, Departments of Surgery and
Search for more papers by this authorAndrew M Scott
Ludwig Institute for Cancer Research, and
Medicine,
Centre for Positron Emission Tomography, Austin Hospital, Heidelberg, Victoria, Australia
Search for more papers by this authorNathan Lawrentschuk,
Ian D Davis,
Damien M Bolton,
Andrew M Scott,
Corresponding Author
Nathan Lawrentschuk
University of Melbourne, Departments of Surgery and
Ludwig Institute for Cancer Research, and
Dr Nathan Lawrentschuk, md, 10 Mary Street, Beaumaris, Vic. 3193, Australia. Email: [email protected]Search for more papers by this authorIan D Davis
Ludwig Institute for Cancer Research, and
Medicine,
Search for more papers by this authorDamien M Bolton
University of Melbourne, Departments of Surgery and
Search for more papers by this authorAndrew M Scott
Ludwig Institute for Cancer Research, and
Medicine,
Centre for Positron Emission Tomography, Austin Hospital, Heidelberg, Victoria, Australia
Search for more papers by this authorAbstract
Abstract: Nuclear medicine techniques continue to be important non-invasive imaging tools assisting the diagnosis, monitoring and – in some cases – treatment of prostate cancer. Bone scintigraphy was the premier modality to have an extensive role in the staging of prostate cancer and has remained an integral tool for over three decades in the assessment of newly diagnosed disease or in follow-up staging. Therapeutic treatment and palliation of disseminated disease, particularly in the skeleton, has also been successful with several radioisotopes including strontium-89 chloride. Despite advances in nuclear medicine techniques and molecular imaging technology such as positron emission tomography and radioimmunoscintigraphy, bone scintigraphy still remains the gold standard in the assessment of osseous metastatic disease in prostate cancer. Thus, it is important to continually review the modalities that have remained important over time and not just to focus on newer technologies. This article summarizes the current diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer with particular reference to radionuclide bone scintigraphy and positron emission tomography.
References
- 1 Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57–60.
- 2 Brown ML. Bone scintigraphy in benign and malignant tumors. Radiol. Clin. North Am. 1993; 31: 731–8.
- 3 Prvulovich EM, Bomanji JB. The role of nuclear medicine in clinical investigation. BMJ 1998; 316: 1140–6.
- 4 Malhotra P, Berman CG. Evaluation of bone metastases in lung cancer. Improved sensitivity and specificity of PET over bone scanning. Cancer Control 2002; 9: 254, 259–60.
- 5 Peterson JJ, Kransdorf MJ, O’Connor MI. Diagnosis of occult bone metastases: positron emission tomography. Clin. Orthop. 2003; 415: S120–8.
- 6 Saad F, Gleason DM, Murray R. et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst. 2004; 96: 879–82.
- 7 Roudier MP, Vesselle H, True LD et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin. Exp. Metastasis 2003; 20: 171–80.
- 8 Schaffer DL, Pendergrass HP. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 1976; 121: 431–4.
- 9 Andriole GL, Coplen DE, Mikkelsen DJ, Catalona WJ. Sonographic and pathological staging of patients with clinically localized prostate cancer. J. Urol. 1989; 142: 1259–61.
- 10 Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J. Urol. 1991; 145: 313–18.
- 11 Lee N, FawaaZ. R., Olsson CA et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48: 1443–6.
- 12 Wolff JM, Zimny M, Borchers H, Wildberger J, Buell U, Jakse G. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur. Urol. 1998; 33: 376–81.
- 13 Gleave ME, Coupland D, Drachenberg D et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708–12.
- 14 Rudoni M, Antonini G, Favro M et al. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur. J. Nucl. Med. 1995; 22: 207–11.
- 15 Haukaas S, Roervik J, Halvorsen OJ, Foelling M. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br. J. Urol. 1997; 79: 770–6.
- 16 Lee CT, Oesterling JE. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol. Clin. North Am. 1997; 24: 389–94.
- 17
Wymenga LF,
Boomsma JH,
Groenier K,
Piers DA,
Mensink HJ.
Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.
BJU Int.
2001; 88: 226–30.
10.1046/j.1464-410x.2001.02275.x Google Scholar
- 18 Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J. Urol. 2004; 171: 2122–7.
- 19 Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin. Nucl. Med. 2004; 34: 274–92.
- 20 Terris MK, Klonecke AS, McDougall IR, Stamey TA. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J. Nucl. Med. 1991; 32: 1713–17.
- 21 Lawrentschuk N, Webb DR, Mitchell CA. Metastatic prostate cancer to lung with normal prostate specific antigen levels. Hosp. Med. 2004; 65: 116–7.
- 22 Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int. 2001; 87: 348–51.
- 23 Ornstein DK, Colberg JW, Virgo KS et al. Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology 1998; 52: 1047–54.
- 24
Tsai DY,
Virgo KS,
Colberg JW et al.
The age of the urologist affects the postoperative care of prostate carcinoma patients.
Cancer
1999; 86: 1314–21.
10.1002/(SICI)1097-0142(19991001)86:7<1314::AID-CNCR29>3.0.CO;2-K CAS PubMed Web of Science® Google Scholar
- 25 Cher ML, Bianco FJ Jr, Lam JS et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J. Urol. 1998; 160: 1387–91.
- 26 Kane CJ, Amling CL, Johnstone PA et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003; 61: 607–11.
- 27 GomeZ. P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int. 2004; 94: 299–302.
- 28 Jhaveri FM, Klein EA. How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure. Semin. Urol. Oncol. 1999; 17: 130–4.
- 29 Thurairaja R., McFarlane JP, Persad R. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int. 2005; 95: 189–90.
- 30 SeitZ. C, Remzi M, Djavan B. Immediate treatment after PSA progression. Eur. Urol. Suppl. 2005; 4: 28–42.
- 31 Dotan ZA, Bianco FJ Jr, Rabbani F et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J. Clin. Oncol. 2005; 23: 1962–8.
- 32
Corrie D,
Timmons JH,
Bauman JM,
Thompson IM.
Efficacy of follow-up bone scans in carcinoma of the prostate.
Cancer
1988; 61: 2453–4.
10.1002/1097-0142(19880615)61:12<2453::AID-CNCR2820611211>3.0.CO;2-P CAS PubMed Web of Science® Google Scholar
- 33 Yap BK, Choo R., Deboer G, KlotZ. L, Danjoux C, Morton G. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone? BJU Int. 2003; 91: 613–17.
- 34 Freitas JE, Gilvydas R., Ferry JD, GonzaleZ. JA. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up. J. Nucl. Med. 1991; 32: 1387–90.
- 35 Bushnell DL, Madsen M, Kahn D, Nathan M, Williams RD. Enhanced uptake of 99tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents. Nucl. Med. Commun. 1999; 20: 875–81.
- 36 Rigaud J, Tiguert R., Le Normand L et al. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J. Urol. 2002; 168: 1423–6.
- 37 Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br. J. Cancer 2003; 88: 195–201.
- 38 Cook GJ, Fogelman I. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography. Q. J. Nucl. Med. 2001; 45: 47–52.
- 39 Schoder H, Herrmann K, Gonen M et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin. Cancer Res. 2005; 11: 4761–9.
- 40 Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18) F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J. Cancer Res. Clin. Oncol. 2002; 128: 325–8.
- 41 Cook GJ, Houston S, Rubens R., Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J. Clin. Oncol. 1998; 16: 3375–9.
- 42 Nakamoto Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clin. Nucl. Med. 2003; 28: 302–7.
- 43 Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin. Nucl. Med. 2006; 36: 73–92.
- 44 Morris MJ, Akhurst T, Osman I et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002; 59: 913–18.
- 45 Even-Sapir E, Metser U, Flusser G et al. Assessment of malignant skeletal disease. Initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J. Nucl. Med. 2004; 45: 272–8.
- 46 Ghanem N, Uhl M, Brink I et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur. J. Radiol. 2005; 55: 41–55.
- 47 Campa JA III, Payne R. The management of intractable bone pain: a clinician’s perspective. Semin. Nucl. Med. 1992; 22: 3–10.
- 48 Robinson RG, Preston DF, Spicer JA, Baxter KG. Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin. Nucl. Med. 1992; 22: 28–32.
- 49 Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274: 420–4.
- 50 Maxon HR III, Thomas SR, Hertzberg VS et al. Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin. Nucl. Med. 1992; 22: 33–40.
- 51 Han SH, de Klerk JM, Tan S et al. The placorhen study: a double-blind, placebo-controlled, randomized radionuclide study with (186) re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo controlled rhenium study. J. Nucl. Med. 2002; 43: 1150–6.
- 52 Collins C, Eary JF, Donaldson G et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J. Nucl. Med. 1993; 34: 1839–44.
- 53 Turner JH, Martindale AA, Sorby P et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur. J. Nucl. Med. 1989; 15: 784–95.
- 54 Srivastava SC, Atkins HL, Krishnamurthy GT et al. Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin. Cancer Res. 1998; 4: 61–8.
- 55 Sartor O. Radioisotopic treatment of bone pain from metastatic prostate cancer. Curr. Oncol. Rep. 2003; 5: 258–62.
- 56 Oyen WJ, Witjes JA, Corstens FH. Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma. Eur. Urol. 2001; 40: 294–9.
- 57 Silberstein EB, Eugene L, Saenger SR. Painful osteoblastic metastases: the role of nuclear medicine. Oncology (Huntingt) 2001; 15: 157–63; discussion 167–170, 174.
Citing Literature
